DIOVAN HCT NEWS HIGHLIGHTS Media Articles Related to Diovan HCT (Valsartan / Hydrochlorothiazide)
New Product For Pfizer Specialty Takes Pulmonary Arterial Hypertension To Heart
Source: Health News from Medical News Today [2009.07.02]
Pfizer Australia announced that it has signed an agreement to acquire the local distribution rights for THELIN® (Sitaxentan sodium), an oral, once-daily highly selective endothelin receptor antagonist, indicated for the treatment of pulmonary arterial hypertension (PAH) in patients with NYHA/WHO Functional Class III symptoms to improve exercise ability.
Rat Model Of Hepatic Encephalopathy And Prehepatic Portal Hypertension
Source: GastroIntestinal / Gastroenterology News From Medical News Today [2009.06.30]
A research article published in the World Journal of Gastroenterology refers. The research team lead by Dr. Gabriela Beatriz Acosta, observed that the activity of GS was increased in the hippocampus in PH rats. There was a significant decrease in glutamate uptake in both brain areas, which was more marked in the hippocampus. The decrease in glutamate uptake might be caused by deficient transport function and persistent glutamate activity, which is not metabolized.
Sporadic Spikes in Blood Pressure Hike Chances of Hypertension
Source: MedicineNet Cholesterol Specialty [2009.06.30]
Title: Sporadic Spikes in Blood Pressure Hike Chances of Hypertension
Category: Health News
Created: 6/30/2009 7:00:00 AM
Last Editorial Review: 6/30/2009
White-Coat Hypertension Not Benign
Source: MedicineNet Exercise and Activity Specialty [2009.06.30]
Title: White-Coat Hypertension Not Benign
Category: Health News
Created: 6/30/2009
Last Editorial Review: 6/30/2009
'White-Coat' Hypertension May Persist Over Time (CME/CE)
Source: MedPage Today Cardiovascular [2009.06.29]
SAN FRANCISCO (MedPage Today) -- Sporadic hypertension, whether just in the doctor's office or only occasionally at home, substantially increases risk of later sustained hypertension, researchers found.
Published Studies Related to Diovan HCT (Valsartan / Hydrochlorothiazide)
Randomized, Double-blinded Trial Evaluation of Valsartan/Hydrochlorothiazide Combination Therapy in Mild to Moderate Essential Hypertension in North-east China. [2008.07]
In this randomized, double-blind study, 126 mild to moderate essential hypertensive patients from northern China were studied to determine the efficacy and safety of a combination therapy of valsartan and hydrochlorothiazide. Patients were randomized to the V80/H12.5 (80 mg valsartan/12.5 mg hydrochlorothiazide) group or the V80 (80 mg valsartan) group.
Combination therapy with valsartan/hydrochlorothiazide at doses up to 320/25 mg improves blood pressure levels in patients with hypertension inadequately controlled by valsartan 320 mg monotherapy. [2008.06]
OBJECTIVES: To investigate the efficacy and tolerability of valsartan (Val) 320 mg once daily (o.d.), Val/hydrochlorothiazide (HCTZ) 320/12.5 mg o.d. and Val/HCTZ 320/25 mg o.d. in patients with hypertension not adequately controlled by Val monotherapy... CONCLUSIONS: The combination ofVal and HCTZ at doses of 320/12.5 mg and 320/25 mg increases antihypertensive efficacy in patients with mild-to-moderate hypertension inadequately controlled with Val 320 mg monotherapy, without compromising tolerability.
Combination therapy with valsartan/hydrochlorothiazide at doses up to 320/25 mg improves blood pressure levels in patients with hypertension inadequately controlled by valsartan 320 mg monotherapy. [2008.01.24]
Objectives... The combination of Val and HCTZ at doses of 320/12.5 mg and 320/25 mg increases antihypertensive efficacy in patients with mild-to-moderate hypertension inadequately controlled with Val 320 mg monotherapy, without compromising tolerability.
[Therapeutic efficacy of valsartan and valsartan/HCTZ in mild to moderate hypertensive patients] [2007.08]
OBJECTIVE: To assess the efficacy and safety of valsartan/hydrochlorothiazide [generic for Diovan HCT] (HCTZ) 80/12.5 mg once daily (o.d.) in Chinese patients with mild to moderate essential hypertension who was not adequately controlled by valsartan 80 mg o.d. monotherapy... CONCLUSION: Efficacy of Valsartan 80 mg/HCTZ 12.5 mg compound was superior to valsartan 80 mg on BP reduction and goal BP control rate in Chinese patients with mild to moderate essential hypertension. The combination of Valsartan 80 mg/hydrochlorothiazide (HCTZ) 12.5 mg provides a suitable treatment for Chinese patients who are not adequately controlled by valsartan 80 mg o.d. monotherapy.
Aliskiren, an orally effective Renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. [2007.01]
BACKGROUND: By blocking the renin-angiotensin-aldosterone system (RAAS) at its rate-limiting step, renin inhibition may provide improved RAAS suppression. We investigated the blood pressure (BP)-lowering effects of the oral direct renin inhibitor aliskiren, alone or in combination with the angiotensin receptor blocker valsartan... CONCLUSIONS: Aliskiren monotherapy provides antihypertensive efficacy and placebo-like tolerability in patients with hypertension. Aliskiren and valsartan in combination may provide additive BP-lowering effects with maintained tolerability.
Clinical Trials Related to Diovan HCT (Valsartan / Hydrochlorothiazide)
A Safety and Tolerability Study of the Combination of Aliskiren/Valsartan in Patients With High Blood Pressure, Followed by Long-Term Safety and Tolerability of Aliskiren, Valsartan and Hydrochlorothiazide. [Active, not recruiting]
Assessment of the long-term safety and tolerability of the combination of aliskiren and
valsartan (300 mg/ 320 mg) in patients with high blood pressure,followed by assessment of
long-term safety and tolerability of the combination of aliskiren/valsartan/HCTZ.
A Study in Chinese Mild to Moderate Hypertensive Patients Comparing the Efficacy of Co-Diovan With Diovan. [Completed]
Valsartan, an orally active angiotensin II receptor blocker, is registered in most countries
worldwide for the treatment of hypertension. In China the usual recommended starting and
maintenance dose is 80 mg o. d. The combination of HCTZ 12. 5 mg with valsartan 80 mg has been
shown to have additive effects in lowering blood pressure compared to valsartan 80 mg in
patients not adequately controlled by valsartan 80 mg monotherapy5 or in non-selected
patients6. This fixed combination is registered in most countries worldwide.
The potential benefits of these combinations should be evaluated in patients not adequately
controlled by valsartan 80 mg monotherapy. This study will compare the efficacy, safety and
tolerability of adding HCTZ 12. 5 mg to valsartan 80 mg in those hypertensive patients.
This study is not recruiting in the US.
To Compare the Blood Level of Marketed Japanese Valsartan Tablet Formulation vs Global Valsartan Tablet Formulation in Healthy Volunteers [Completed]
The purpose of this study is to assess how the body changes the blood level of single dose of
valsartan 160 mg tablet Japanese formulation and valsartan 160 mg tablet global formulation
under fasting condition in healthy volunteers.
8-Week Study to Evaluate Safety and Efficacy of Various Combinations of Valsartan, HCTZ, and Amlodipine in Patients With Moderate to Severe Hypertension [Completed]
The purpose of this study is to determine the safety and efficacy of the various combinations
of valsartan, HCTZ, and amlodipine in patients with moderate to severe hypertension.
Bioavailability of Aliskiren and Valsartan Combined as a Single Tablet vs. the Same Medications Given Separately to Healthy Subjects. [Completed]
This study will assess the bioavailability of aliskiren and valsartan as a single tablet
compared to the same doses of the two drugs given as two separate tablets in healthy
subjects.
|
